Success in a Phase 2 trial of umbilical-cord-derived allogeneic mesenchymal stromal cells (MSCs) for newly diagnosed Type 1 diabetes.

[jeffreyn]

"No other treatments on the market or in clinical trials have shown the ability to halt the progression of diabetes."

Medical Xpress article: Wharton's jelly found to halt diabetes progression in Phase II trial.

medicalxpress.com/news/2023...

Research paper (open access): Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial.

link.springer.com/article/1...